We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Eden Biodesign Signs Marketing Services Agreement with Human Genome Sciences

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Eden Biodesign Ltd. announced that they have entered into a marketing services agreement with Human Genome Sciences, Inc.

Under the terms of the agreement, Eden Biodesign will use its expertise and global presence in the biopharmaceutical contract manufacturing market to assist HGS in identifying new manufacturing clients for its large scale commercial cell culture production facilities located in Rockville, MD.

Both companies will use their combined expertise in process development, process scale-up, technology transfer, analytical and international regulatory support for biopharmaceuticals to provide customers with transition into cGMP manufacturing at scales up to 20,000L and access to commercial production capacity for biopharmaceuticals derived from mammalian cell culture.

“This alliance is particularly significant for Eden Biodesign and we are delighted that such a prestigious company as Human Genome Sciences has recognized Eden Biodesign’s technical excellence, global marketing reach and strong track record” commented Dr. Crawford Brown, Chief Executive Officer of Eden Biodesign.

“In addition to our process development and clinical scale cGMP production services, our growing portfolio of successful clients may now also have seamless access to Human Genome Sciences’ world leading expertise in late-stage process development and state-of-the-art large scale production facilities as their products progress towards, and in to, commercial launch”.